Autologous mesenchymal stem cell transplantation ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	3

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01377870 (ClinicalTrials.gov)	December 2011	19/6/2011	Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis	Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis	Multiple Sclerosis	Biological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free media	Royan Institute	NULL	Completed	18 Years	55 Years	All	22	Phase 1/Phase 2	Iran, Islamic Republic of
2	NCT00813969 (ClinicalTrials.gov)	March 2011	22/12/2008	Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS	A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple Sclerosis	Relapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis	Biological: Autologous mesenchymal stem cell transplantation	The Cleveland Clinic	University Hospital Case Medical Center	Completed	18 Years	55 Years	Both	24	Phase 1	United States
3	NCT01228266 (ClinicalTrials.gov)	December 2010	25/10/2010	Mesenchymal Stem Cell Transplantation in MS	Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II Study	Multiple Sclerosis	Biological: autologous mesenchymal stem cells	Albert Saiz	Instituto de Salud Carlos III	Terminated	18 Years	50 Years	Both	9	Phase 2	Spain